QuVa Pharma Inc, Temple, TX

Is QuVa Pharma Inc registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels its entry 503B, with FDA’s note “Out of business”.

Does QuVa Pharma Inc hold a Texas pharmacy license?

No license with this exact name and city was found in the Texas State Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file does list QUVA PHARMA, INC, SUGAR LAND, a close but not exact match shown below. The Delaware Division of Professional Regulation also lists nonresident license AD-0000025 for QuVa Pharma, Inc., TEMPLE, TX, status Closed, as of Nov 10, 2026.

Has QuVa Pharma Inc had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 FMD-145 letter (Jan 3, 2023) for QuVa Pharma Inc. Texas board disciplinary orders: not checked, because the board’s file flags orders only on a license, and no license matched this name and city.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
QuVa Pharma Inc
Location
Temple, TX
Type as FDA labels it
503B
FDA’s note
Out of business
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
2
Warning letters on FDA’s actions page
0
Latest action on that page
Jan 3, 2023
FDA Data Dashboard inspections
6 inspections: 3 OAI, 3 VAI; 9 published Form 483s
Form 483 text on this page
4 Form 483s, 21 observations
State board records
No exact match

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as QuVa Pharma Inc, a 503B facility, with 3 dated actions.

Document
Jan 3, 2023FMD-145 letterFMD-145 Issued 01/3/2023Not linked by FDA
Jun 16, 2022Form 483483 Issued 06/16/2022FDA copy (archived)
Mar 14, 2019Form 483483 Issued 03/14/2019FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists QuVa Pharma, Inc., Temple, TX (FEI number 3002468086), matched to this page by exact name, city and state. It lists 6 inspections: 3 OAI, 3 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Jun 16, 2022Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30024680861172047
Mar 14, 2019Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30024680861083122
Dec 8, 2016Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)3002468086995263
Jan 23, 2015Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)3002468086912138
Jun 20, 2014Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3002468086885230
Apr 2, 2014Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3002468086871355

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 21 numbered observations in all, across 4 inspections ending Dec 8, 2016 to Jun 16, 2022. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Jun 7, 2022 to Jun 16, 2022: 4 observations

Firm on the cover
QuVa Pharma, Inc., 5920 S General Bruce Dr Ste 100, Temple, TX 76502-5804
FEI number
3002468086
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
1201 Main Street, Suite 7200 Dallas, TX 75202
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Aseptic processing areas are deficient in that floors are not smooth and/or hard surfaces that are easily cleanable.

Specifically, on 6/7/2022, while performing visual observations of the firm's production of drug products intended to be sterile, in Cleanroom we observed the floor in the ISO 7 Cleanroom, which contains the ISO 5 BSC was found to have propagating cracks from a hole (approximately 1" height x approximately 2.5" length) in the epoxy flooring exposing the floor base material resulting in potential causing difficult to adequately clean and disinfect floor along with potentially harboring microbial contamination. Your firm's PIC was unaware of the ISO 7 Floor condition.

Observation 2

Input to and output from the computer and records or data are not checked for accuracy.

Specifically, during a review of your fnm's batch record, your fnm was found to be use an unvalidated online software, <Redacted B4> to determine your firm's documented BUD found on your firm's bulk drug finish product labeling. For example, while reviewing your fnm's batch record for non-sterile bulk concentrate, Ephedrine Sulfate <Redacted B4> Bulk Bag_ 50 mg/mL 3000 mL Bag Preservative Free, Date Compounded 6/3/2022, Exp: J 673072022, Lot # <Redacted B4> and <Redacted B4> sterile bulk Ephedrine Sulfate <Redacted B4> Bulk # <Redacted B4> Bag 5 mg/mL 3000 mL Bag Preservative Free, Date Compounded 6/8/2022, Exp: 7/5/2022, Lot <Redacted B4>, was found to contain a print-out from the online software, <Redacted B4>. Your firm Quality Manager stated your firm had not verified the accuracy of the online software used to determine drug product BUDs. Your firm management state the software use had been in place since the acquisition.

software use had been in place since the acquisition.

Observation 3

The master production and control records are deficient in that they do not include complete manufacturing and instructions.

Specifically,

A. During a review of selected bulk batch record for the non-sterile bulk drug concentrates, Ephedrine Sulfate <Redacted B4> concentrate, <Redacted B4> Bulk Bag 50mg/mL 3000 mL Bag, Lot# <Redacted B4> , Compound date 6/3/2022, Exp. 6 30/2022 <Redacted B4> to compound the bulk L finished drug batch Ephedrine Sulfate PF 5mg/mL in NaCl 3L Bulk Bag, Lot # <Redacted B4>, Compound Date 6/8/2022, Expiiy 7/5/2022, failed to include instruction and documentation for placing non-sterile bulk concentrate bag into a <Redacted B4> bag to prevent light penetration resulting in the potential degradation of the product. Your firm's quality manager stated the <Redacted B4> requirement for concentrate bulk solutions was an oversight in the master batch record.

B. ...

Read the full 483 (PDF on fda.gov)

Observation 4

The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(I0)(A). Specifically, the following information is not found on your drug product labels:

A. The established name of the drug; Examples of your drug product labels that do not contain this information:

contain this info1mation:

1. L.E.T. Solution 3 ml in 5 ml TS

2. L.E.T. Gel 1.5 ml in 3 ml Top Syr.

3. L.E.T. Gel 3 ml in 5 ml TS

Inspection dated Mar 14, 2019 by FDA (dates on the form not read): 9 observations

Firm on the cover
QuVaPharma. Inc., 'V 5920 S. General Bruce Drive, Temple, TX 76502
FEI number
3002468086
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
4040 N. Central Expressway, #300 Dallas, TX 75204
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov); FDA also posts it as https://www.fda.gov/media/123660/download

Observation 1

Written procedures are lacking which describe in sufficient detail the receipt, identification, approval, and rejection ofcomponents.

Specifically, your firm is using non-pharmaceutical grade components in the formulation of sterile drug products. For example,

a) Your firm uses <Redacted B4> for adjusting the pH of sterile drug products. The <Redacted B4> is labeled ''NOT FOR DRUG, FOOD, OR HOUSEHOLD USE".

b) Your firm uses <Redacted B4> for adjusting the pH of sterile drug products.

Observation 2

There are no established written methods of cleaning or methods of processing to remove pyrogenic properties.

Specifically, your firm has not validated the depyrogenation process for the <Redacted B4> used in compounding sterile drug products. Your firm has not demonstrated that the washing process you have implemented is adequate for endotoxin removal.

Add Continuation Page

Your firm had a confirmed endotoxin failure in January 2019 (Finished product lot #10019623 of Heparin PF 0.2

5 <Redacted B 4> mL 0.5 N S -Bulk lot # <Red atcted B4>

Observation 3

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

a) In January 2019, your firm removed the <Redacted B4> in a <Redacted B4> Iso 7 Cleanrooms that were <Redacted B4> • As part of the change control, your firm did not perform an assessment to justify how you are bringing the materials into the cleanroom or if any changes were needed to the environmental monitoring program as a result of the change.

b) Your firm is not sampling sites that are frequently touched during production such as the surface of the <Redacted B4> Repeater Pump and the door handle from the ISO 7 Cleanroom into the ISO 8 Gowning/ Ante Room.

Observation 4

The separate or defined areas and control systems necessary to prevent contamination or mix-ups are deficient.

Specifically, rust and residue could be seen on the metal hinges of the totes used to hold and bring items into and out of the ISO 7 Cleanroorns and/or the ISO 8 Gowning/Ante Rooms, including empty sterile bags used for filling the sterilized product into; packages containing sterile tubing, <Redacted B4> and environmental monitoring plates; and bags with the <Redacted B4> drug product. Rust was also noted on the wheels of the trash cart in the ISO 7 Cleanroom <Redacted B4> :and the inside of the lid on the trash can in the ISO 8 Gowning/Ante Room for Cleanroom <Redacted B4>

Add Continuation Page

Observation 5

Production personnel were not practicing good sanitation and health habits.

Specifically, your firm does not have handwashing facilities near the gowning areas for entry into compounding areas, including entry into ISO 7 Cleanrooms/1SO 5 <Redacted B4> In addition, your written procedures regarding gowning do not require hand washing.

Observation 6

Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that components, in-process materials, and drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically, your firm has not validated the incubation temperature and time for growth Qromotjon of media and <Redac ted B4> the environmental and personnel monitoring plates. Your firm is incubating the plates at <Redacted B4> degrees C <Redacted B4>

Observation 7

You compound drugs that are essentially a copy of one or more approved drugs within the meaning of sections 503B <Redacted B4> and 503B <Redacted B4> Specifically, you compound drug products that: a) are identical or nearly identical to an approved drug that is not on the drug shortage list in effect under section 506E at the time of compounding, distribution, and dispensing; or b) are not identical or nearly identical to an approved drug, but contain a bulk drug substance that is also a component of an approved drug, and for which there is no change that produces for an individual patient a clinical difference, as determined by the prescribing practitioner, between the compounded drug and the comparable approved drug.

Add Continuation Page

Examples of compounded drug products that are essentially a copy of one or more approved drugs include:

Neostigmine methylsulfate 1mg/1ml

Glycopyrrolate 0.2mg/ml

Midazolam PF lmg/ml

Observation 8

The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(l0)

(A). Specifically, the following information is not found on your drug product labels:

a) The statement "This is a compounded drug";

b) MMA 3/14/19 3

· rnf<' ~ '3 V c) The dosage form and MMA 3/14/19 (v1 \9

d) MMA 3/14/19

e) The National Drug Code number, ifavailable;

f) The statement "Not for resale", and, ifthe drug is dispensed or distributed other than pursuant to a prescription for an individual identified patient, the statement "Office Use Only";

g) MMA 3/14/19 MMA 3/14/19 MMA 3/14/19MMA 3/14/19

Add Continuation Page

Examples of your drug product labels that do not contain this information include:

Fentanyl lOmcg/mL Preservative Free (PF) 3000mL bag

Morphine Sulfate Pentahydrate lmg/mL PF 3000mL bag

Fentanyl/Ropivacaine HCL PF 2mcg/ml/0.2% 3000mL bag

Diltiazem HCL lmg/mL PF 3000mL bag

Amiodarone HCL 1.8mg/rnL 3000mL bag

Observation 9

The containers of your outsourcing facility's drug products does not include information required by section 503B (a)(lO)(B). Specifically, your containers do not include the following information:

a) Information to facilitate adverse event reporting: www.fda.gov/medwatch and 1-800-FDA-1088;

Examples of your container labels that do not contain this information include:

Fentanyl lOmcg/mL PF 3000mL bag

Morphine Sulfate Pentahydrate lmg/mL PF 3000mL bag

Fentanyl/Ropivacaine HCL PF 2mcg/m1/0.2% 3000mL bag

Diltiazem HCL lmg/mL PF 3000mL bag

Amiodarone HCL l.8mg/mL 3000mL bag

Acid Continuation Page

b) Route of administration.

Examples of drug product containers that do not contain this information:

Fentanyl lOmcg/mL PF 3000ml bag

Morphine Sulfate Pentahydrate lmg/mL PF 3000mL bag

Fentanyl/Ropivacaine HCL PF 2mcg/ml/0.2% 3000mL bag

Diltiazem HCL 1 mg/mL PF 3000mL bag

Amiodarone HCL l.8mg/mL 3000mL bag

Add Continuation Page

Inspection Apr 16, 2018 to Apr 20, 2018: 4 observations

Firm on the cover
, 5920 S General Bruce Dr QuVa Pharma, Inc ., Temple, TX 76502- 5804
FEI number
3002468086
Establishment type on the cover
Ou tsourcing Facili ty
FDA district office on the cover
Dallas, TX 75204
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

The quality control unit lacks authority to fully investigate en ors that have occuned.

A. Negative controls run with < Redacted B4> testing intended to determine sterility of human drug pr oducts shows anomalous/unexp ected dat that has not been investigated or trended per SOP #QS-0012 rev 3 (effective May 2017). For example; 16 November 2017, negative control showed <Redacted B4> "events" while Oxytocin, Cefazolin, and Sodium Bicarb product tested concurrently that day were dispositioned as sterile. 2 November 2017, product Oxytocin in Lactated Ringers showed <Redacted B4> "events" in Lot #10006280 and product was dispositioned as sterle. <Redacted B4> test methodology requires a human review of <Redacted B4> "events" to determine if each instance represents a microorganism in the tested sample.

16 November 2017, negative control showed~ "events" while Oxytocin, Cefazolin, and Sodium Bicarb product tested concun ently that day were dispositioned as ste1ile

4 2 November 2017, product Oxytocin in Lactated Ringers showed~bH l "events" in Lot #10006280 and product was dispositioned as sterile ...

Read the full 483 (PDF on fda.gov)

Observation 2

Written records of investigation of a drug complaint do not include the findings of the investigation.

Complaint records do not include the applicable formulation records or identify the location of bulk product formulation. For example:

Complaint #1700040 for possible sub-potent product dated 9 August 2017 was documented without investigating the formulation batch or documenting the Quva location where formulation occurred. The complaint product was injectable Neostigmine lmg/mL syringes.

Complaint #1700034 for possible sub-potent product dated 13 July 2017 was documented without investigating the formulation batch or documenting the Quva location where formulation occurred. The complaint product was injectable Rocmonium PF 1 Omg/mL syringes.

Observation 3

There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.

Specifically, there is no supporting data to show that <Redacted B4> (Model ' <Redacted B4>is appropriate for sterilizing up to <Redacted B4> of bulk in-process dug product.

To date, the closest relevant data is non-sterile <Redacted B4> media simulation (lot#TTX641) <Redacted B4> sterilized sterilized to show maximum process of <Redacted B4>.

Ephedrine Sulfate bulk lot #TTX224 ~ was < Redacted B4> sterilized using <Redacted B4>. A portion of this bulk was filled into <Redacted B4> finished product syringes on 26 February 2018 as part of lot #20002610. The syringes were released by the quality unit and shipped on 16 March 2018.

Observation 4

Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to aseptic processing of drug products.

Specifically, your firm utilized pass-through boxes for each of the clean rooms <Redacted B4> and <Redacted B4> where bulk sterile injectable products such as Morphine Sulfate and Ketamine lOmg/mL are produced. This creates a route of communication between unclassified areas and ISO 7 clean rooms.

Inspection Nov 28, 2016 to Dec 8, 2016: 4 observations

Firm on the cover
Outsourcing Facility, 5920 S General Bruce Dr Ste 100, Temple, TX 76502-5804
FEI number
3002468086
FDA district office on the cover
Dallas, TX 75204
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the equipment to produce aseptic conditions.

Specifically, your firm has not performed effectiveness testing for disinfectants such as redacted (b) (4) and redacted (b) (4) which are routinely used in the ISO 5 redacted (b) (4) I Specifically, your firm has not performed effectiveness testing for disinfectants such as redacted (b) (4) and redacted (b) (4) which are routinely used in the ISO 5 redacted (b) (4 )

S pecifically, your firm has not performed effectiveness testing for disinfectants such as redacted (b) (4) and redacted (b) (4) which are routinely used in the ISO 5 redacted (b) (4)

Observation 2

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically, your firm failed to record continuous pressure differentials between the ISO 5 redacted (b) (4) and ISO 7 Clean Rooms during aseptic drug production. l Specifically, your firm failed to record continuous pressure differentials between the ISO 5 redacted (b) (4) and ISO 7 Clean Rooms during aseptic drug production.

In addition, the pressure gauges measuring the pressure differential from the r edacted (b) (4) to the redacted (b) (4) are not equipped with an alarm system as required in Section 4.2 of your firm's Standard Operating Procedure (SOP), QuVa Pharma Facility Standard, Document COR-SOP-T0-0002, Version 01, Effective date 7/8/2016. l In additi on, the pressure gauges measuri ng the pressure dif ferential from the redacted (b) (4) to the redacted (b) (4) are not equipped w ith an alarm system as required in Section 4.2 of your firm's Standard Operating Procedure (SOP), QuVa Pharma Facility Standard, Document COR-SOP-T0-0002, Version 01, Effective date 7/8/2016.

Observation 3

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

Specifically, your redacted (b) (4) 1 Certification Report" dated redacted (b) (4) for each redacted (b) (4) includes an "Air Flow Smoke Pattern Test". In each case, there was no documentation to show that the test was performed under dynamic conditions.

Observation 4

The labels of your outsourcing facility's drug products are deficient.

Specifically, your labels do not include the address and phone number of the site under inspection. For example,

• Norepinephrine 8 mg added to 5% Dextrose 500ml Bag • Promethazine HCI25mg added to 0.9% Sodium Chloride • Ephedrine Sulfate 5mg/ml in 0.90% Sodium Chloride

Linked 483s whose text is not shown

State board of pharmacy records

No license with this exact name and city was found in the Texas State Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. Board file.

What this covers: The file marks whether a license has prior disciplinary orders (column DISP ACTN, Y or N) but does not list them; the orders are on the board’s license lookup, which this index does not copy. The board says orders entered more than 10 years ago are not online.

Close but not exact board records

These board records share a name with this pharmacy but did not meet this index’s matching rule (same name, same city, same state), so they are not treated as its license. They may belong to a separate business.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
AD-0000025Outsourcing Facility-DistributorQuVa Pharma, Inc.TEMPLE, TXClosed

Same name at other locations

FDA lists these records under the same name at another location. A shared name does not establish that they are the same firm.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.